- Home
- ACRV vs CPSS Comparison
ACRV vs CPSS Comparison
Compare ACRV & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- CPSS
- Stock Information
- Founded
- ACRV 2018
- CPSS 1991
- Country
- ACRV United States
- CPSS United States
- Employees
- ACRV N/A
- CPSS N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- CPSS Finance: Consumer Services
- Sector
- ACRV Health Care
- CPSS Finance
- Exchange
- ACRV Nasdaq
- CPSS Nasdaq
- Market Cap
- ACRV 59.9M
- CPSS N/A
- IPO Year
- ACRV 2022
- CPSS 1992
- Fundamental
- Price
- ACRV $1.18
- CPSS $9.88
- Analyst Decision
- ACRV Strong Buy
- CPSS
- Analyst Count
- ACRV 5
- CPSS 0
- Target Price
- ACRV $19.75
- CPSS N/A
- AVG Volume (30 Days)
- ACRV 1.3M
- CPSS 13.3K
- Earning Date
- ACRV 05-13-2025
- CPSS 05-16-2025
- Dividend Yield
- ACRV N/A
- CPSS N/A
- EPS Growth
- ACRV N/A
- CPSS N/A
- EPS
- ACRV N/A
- CPSS 0.79
- Revenue
- ACRV N/A
- CPSS $185,463,000.00
- Revenue This Year
- ACRV N/A
- CPSS $161.83
- Revenue Next Year
- ACRV N/A
- CPSS $15.69
- P/E Ratio
- ACRV N/A
- CPSS $12.51
- Revenue Growth
- ACRV N/A
- CPSS N/A
- 52 Week Low
- ACRV $1.30
- CPSS $7.03
- 52 Week High
- ACRV $10.29
- CPSS $12.73
- Technical
- Relative Strength Index (RSI)
- ACRV 29.23
- CPSS 61.07
- Support Level
- ACRV $1.32
- CPSS $8.76
- Resistance Level
- ACRV $1.50
- CPSS $9.20
- Average True Range (ATR)
- ACRV 0.19
- CPSS 0.40
- MACD
- ACRV 0.06
- CPSS 0.13
- Stochastic Oscillator
- ACRV 2.08
- CPSS 93.57
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.